ABIVAX
FREURABIVAX (LSE:0RA9) — Biotechnology. Number of exchanges where the company shares trade: 4. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- abivax.com
- Investor relations
- abivax.com/investors/
- Sector
- Healthcare · Biotechnology
- Headquarters
- Paris, France
- Management
- Marc M. P. de Garidel
- Employees
- 98
- IPO
- 2015-06-26
- Shares outstanding
- 87.27 M
- Free float
- 69.03 M
- Market cap
- 6.83 B EUR
- Insiders
- 4.17%
- Institutions
- 50.35%
- Industry (SIC)
- Pharmaceutical Preparations
- Legal form
- K65D
- ISIN
- FR0012333284
- LEI
- 969500D8TMNB184OJU95
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- loss
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- −2.47 EUR
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 13.314.1
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- −161 M EUR
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
- ?
- Earnings and FCF — for the 12 months to 31.12.2025 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
advertisement
Exchanges and tickers
| Exchange | Ticker | Currency | Price | Type |
|---|---|---|---|---|
| common stock | ||||
| PA Euronext Paris | ABVX primary | EUR | 77.15 -0.64% | common stock |
| LSE London Stock Exchange | 0RA9 IOB | EUR | 83.8 +0.00% | common stock |
| US USA Stocks | AAVXF OTC | USD | 139 +0.00% | common stock |
| VI Vienna Stock Exchange | ABVX secondary | EUR | 82.55 -1.84% | common stock |
| depositary receipt | ||||
| US USA Stocks | ABVX | USD | 84.25 -5.86% | depositary receipt |
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.23% | 1.08 M | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.78% | 680 945 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.51% | 449 781 | 2026-07-31 |
| Fidelity Concord Street… | 0.27% | 235 822 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.25% | 214 224 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.2% | 175 234 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.2% | 174 657 | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.18% | 156 851 | 2026-05-31 |
| Fidelity Salem Street Tr… | 0.14% | 120 680 | 2026-07-31 |
| TIAA-CREF Funds-Nuveen I… | 0.11% | 97 178 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.07% | 61 715 | 2026-07-31 |
| Guidestone Funds-Interna… | 0.05% | 43 592 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 325 | 2026-06-30 |
Sign in with Google